Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Signal Genetics is all set to launch next generation Multiple Myeloma Predictive Testing Product, MyPRS Plus.
Subscribe to our email newsletter
According to the company, MyPRS Plus helps gain further insights of individual’s genetic characteristics and also determines the molecular sub-group to which each patient belongs.
The relapse and survival available for Myeloma patients can be predicted by classifying the genetic characteristics and molecular sub-groups.
Myeloma Health Research EVP John Shaugnessy said this classification would enable in better understanding of the genetic abnormalities of the patients by the physicians.